We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add NRIX Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
Nurix is advancing bexobrutideg into a phase III study for heavily pretreated CLL/SLL patients.
Roche's deal includes $700M upfront, 60% of development costs and shared U.S. profits and losses.
Nurix plans phase II studies in CSU and MS, broadening bexobrutideg beyond B-cell malignancies.
Nurix Therapeutics (NRIX - Free Report) continues to make steady progress with bexobrutideg, the company’s lead product candidate and primary clinical value driver. Nurix is developing bexobrutideg as an oral, brain-penetrant and highly selective Bruton’s tyrosine kinase (BTK) degrader for B-cell malignancies, with potential expansion into immunology and neurology.
Roche Deal Adds Value to Nurix’s Bexobrutideg
A key positive for the NRIX investment thesis is its global collaboration with Roche (RHHBY - Free Report) , which provides strong validation of bexobrutideg’s potential while helping offset the financial burden of late-stage development. The agreement is valued at up to $2.3 billion, including a $700 million upfront payment. Under the collaboration, Roche will fund 60% of development costs, while Nurix will contribute the remaining 40%. Both companies will co-commercialize bexobrutideg in the United States, with U.S. profits and losses shared equally. Roche will be responsible for commercialization outside the United States, while Nurix will be eligible for tiered royalties on future ex-U.S. sales.
The partnership therefore provides Nurix with access to Roche’s global resources and commercial capabilities while retaining meaningful economic participation in bexobrutideg’s potential success.
Year to date, shares of Nurix have risen 38.5% compared with the industry’s 7.4% growth.
Nurix is advancing bexobrutideg across several stages of development, with the lead focus on relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
The pivotal phase II DAYBreak CLL-201 study is enrolling patients with CLL who have progressed after treatment with a covalent BTK inhibitor, a BCL2 inhibitor and a non-covalent BTK inhibitor. Positive results could potentially support an accelerated approval pathway.
In August, the company enrolled the first patient in the global phase III DAYBreak CLL-306 study evaluating bexobrutidegversus the non-covalent BTK inhibitor pirtobrutinib, in heavily pretreated patients with relapsed/refractory CLL/SLL.Conducted in collaboration with Roche, the study marks an important transition for bexobrutideg into late-stage development.
Nurix plans to evaluate bexobrutideg in combination with venetoclax, with or without an anti-CD20 antibody, in both previously treated and newly diagnosed CLL patients.
NRIX’s Expansion Into Immunology & Neurology
Nurix is developing bexobrutideg for diseases outside cancer, which could increase its future market potential. Early studies suggest that the candidate can strongly reduce BTK activity in immune cells, blood and skin and may control immune responses better than traditional BTK inhibitors. The company is testing a new tablet version in healthy volunteers and plans to advance bexobrutideg into phase II studies for chronic spontaneous urticaria (CSU) and multiple sclerosis (MS).
Additional Pipeline Programs
Nurix has several additional clinical and preclinical programs that could contribute to future growth. Its pipeline includes NRX-0305, NX-1607, NRX-4972 and zelebrudomide. Among these programs, NX-1607 is being evaluated in early-stage studies for solid tumors, while zelebrudomide is being developed for relapsed/refractory B-cell malignancies.
Strategic Partnerships Add Potential Value
In addition to Roche, Nurix has collaborations with big pharmaceutical companies such as Sanofi (SNY - Free Report) , Gilead (GILD - Free Report) and Pfizer. Sanofi is advancing the STAT6 degrader NX-3911, while Gilead is developing the IRAK-4 degrader GS-6791 in a phase I study. Nurix retains rights to potentially share U.S. profits and participate in co-development for these programs after specified development milestones. The company is working with Pfizer on multiple preclinical degrader antibody-conjugate programs and received a $2 million milestone payment from Sanofi in the second quarter of 2026.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Add NRIX Stock to Your Portfolio Now
Key Takeaways
Nurix Therapeutics (NRIX - Free Report) continues to make steady progress with bexobrutideg, the company’s lead product candidate and primary clinical value driver. Nurix is developing bexobrutideg as an oral, brain-penetrant and highly selective Bruton’s tyrosine kinase (BTK) degrader for B-cell malignancies, with potential expansion into immunology and neurology.
Roche Deal Adds Value to Nurix’s Bexobrutideg
A key positive for the NRIX investment thesis is its global collaboration with Roche (RHHBY - Free Report) , which provides strong validation of bexobrutideg’s potential while helping offset the financial burden of late-stage development. The agreement is valued at up to $2.3 billion, including a $700 million upfront payment. Under the collaboration, Roche will fund 60% of development costs, while Nurix will contribute the remaining 40%. Both companies will co-commercialize bexobrutideg in the United States, with U.S. profits and losses shared equally. Roche will be responsible for commercialization outside the United States, while Nurix will be eligible for tiered royalties on future ex-U.S. sales.
The partnership therefore provides Nurix with access to Roche’s global resources and commercial capabilities while retaining meaningful economic participation in bexobrutideg’s potential success.
Year to date, shares of Nurix have risen 38.5% compared with the industry’s 7.4% growth.
Image Source: Zacks Investment Research
Bexobrutideg Progress Strengthens NRIX’s CLL Opportunity
Nurix is advancing bexobrutideg across several stages of development, with the lead focus on relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
The pivotal phase II DAYBreak CLL-201 study is enrolling patients with CLL who have progressed after treatment with a covalent BTK inhibitor, a BCL2 inhibitor and a non-covalent BTK inhibitor. Positive results could potentially support an accelerated approval pathway.
In August, the company enrolled the first patient in the global phase III DAYBreak CLL-306 study evaluating bexobrutidegversus the non-covalent BTK inhibitor pirtobrutinib, in heavily pretreated patients with relapsed/refractory CLL/SLL.Conducted in collaboration with Roche, the study marks an important transition for bexobrutideg into late-stage development.
Nurix plans to evaluate bexobrutideg in combination with venetoclax, with or without an anti-CD20 antibody, in both previously treated and newly diagnosed CLL patients.
NRIX’s Expansion Into Immunology & Neurology
Nurix is developing bexobrutideg for diseases outside cancer, which could increase its future market potential. Early studies suggest that the candidate can strongly reduce BTK activity in immune cells, blood and skin and may control immune responses better than traditional BTK inhibitors. The company is testing a new tablet version in healthy volunteers and plans to advance bexobrutideg into phase II studies for chronic spontaneous urticaria (CSU) and multiple sclerosis (MS).
Additional Pipeline Programs
Nurix has several additional clinical and preclinical programs that could contribute to future growth. Its pipeline includes NRX-0305, NX-1607, NRX-4972 and zelebrudomide. Among these programs, NX-1607 is being evaluated in early-stage studies for solid tumors, while zelebrudomide is being developed for relapsed/refractory B-cell malignancies.
Strategic Partnerships Add Potential Value
In addition to Roche, Nurix has collaborations with big pharmaceutical companies such as Sanofi (SNY - Free Report) , Gilead (GILD - Free Report) and Pfizer. Sanofi is advancing the STAT6 degrader NX-3911, while Gilead is developing the IRAK-4 degrader GS-6791 in a phase I study. Nurix retains rights to potentially share U.S. profits and participate in co-development for these programs after specified development milestones. The company is working with Pfizer on multiple preclinical degrader antibody-conjugate programs and received a $2 million milestone payment from Sanofi in the second quarter of 2026.
Nurix Therapeutics, Inc. Price and Consensus
Nurix Therapeutics, Inc. price-consensus-chart | Nurix Therapeutics, Inc. Quote
NRIX's Zacks Rank
Nurix currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.